We present an audit of cardiovascular risk, and drug prescription of 250 type 2 diabetic patients referred from primary care to a District General Hospital for prescription of 250 type 2 diabetic patients referred from primary care to a District General Hospital for management of insulin therapy. Prescription patterns were compared to current UK guidelines for primary and secondary prevention and evidence-based practice. The audit uncovered substantial under-recognition of the high vascular risk of this type 2 diabetic population with respect to the use of antiplatelet therapy, statins and angiotensin blockers. Type 2 diabetic patients requiring insulin therapy have a particularly high cardiovascular risk and we believe they should be considered for antiplatelet, statin and angiotensin blocking therapy on initiation of insulin treatment even if they have no previous history of overt vascular events.
O'Driscoll G. , Green D., Maiorana A. et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulindependent diabetes mellitus. J Am Coll Cardiol1999;33:1506-11. 3. Festa A., D'Agostino R., JrHoward G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation2000;102:42-7.
3.
Takagi T., Yoshida K., Akasaka T. et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol2000;36:731-8. Metabolism2003;52(8 suppl 1):6-12.
4.
Otel I., Ledru F.,Danchin N.Ischemic heart disease in type 2 diabetes. Metabolism2003;52(8 suppl 1):6:12.
5.
Rumberger JA , Sheedy PF, Breen JF et al. Electron beam computed tomographic coronary calcium score cutpoints and severity of associated angiographic lumen stenosis. J Am Coll Cardiol1997;29:1542-8.
6.
Korpilahti K. , Syvanne M., Engblom E. et al. Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery. Eur Heart J1998;19:711-19.
7.
Arad Y., Newstein D., Cadet F. et al. Association of multiple risk factors and insulin resistance with increased prevalence of asymptomatic coronary artery disease by an electron-beam computed tomographic study. Arterioscler Thromb Vasc Biol2001;21:2051-8.
8.
Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction . N Engl J Med1998;339:229-34.
9.
Grover SA, Coupal L., Zowall H. et al. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated?Circulation2000;102:722-7.
10.
Joint British recommendations on prevention of coronary heart disease in clinical practice.British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart1998;80(suppl 2):S1-29.
11.
Scottish Intercollegiate Guidelines Network (SIGN).Management of diabetes. (SIGN Guideline 55). Edinburgh: SIGN2001 (available on www.sign.ac.uk).
12.
National Institute for Clinical Excellence.Management of type 2 diabetes. Management of blood glucose . NICE No.128, National Institute for Clinical Excellence , London, September 2002.
13.
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet2000;355:253-9.
14.
Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care2001;24: 683-9.
15.
Patel V., Panja S., Venkataraman A.The HOPE and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Br J Diabetes Vasc Dis2001;1: 44-51.
16.
McKee SP , Leslie SJ, LeMaitre JP et al. Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians. Eur J Heart Fail2003;5:549-55.
17.
Fagot-Campagna A., Gary TL, Benjamin SMCardiovascular risk in diabetes: a story of missed opportunities?Diabetes Care2001;24:2015-16.
18.
Collins R., Armitage J., Parish S. et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.
